Sermorelin vs Tesamorelin: How to Choose Between the Two Active GH-Axis Peptides

The GH Axis in One Page

Growth hormone (GH) is released in pulses by your pituitary gland, primarily at night during deep sleep. Most of what GH does actually happens through a second hormone called IGF-1, which your liver makes in response to GH. Together, GH and IGF-1 support body composition (lean mass maintenance, fat metabolism), tissue repair, collagen synthesis, and deep sleep quality.

GH production peaks in adolescence and declines steadily from about age 25. By age 60, most adults produce roughly half the GH they did at 20. This decline is part of what people mean when they say they feel older — slower recovery, reduced sleep depth, thinner skin, harder time maintaining muscle, easier fat accumulation.

The GH-axis peptides — peptides that stimulate the pituitary to produce more GH — are the most direct intervention available. They don't replace the body's system with synthetic hormone (that's what injectable HGH does, with its own risks and legal issues). Instead, they signal the pituitary to produce more of its own GH, keeping the body's natural rhythm — GH released in bursts, with the normal shut-off signals intact.

Sermorelin and Tesamorelin are both GHRH analogs — synthetic versions of the natural GH-releasing hormone (GHRH) that your hypothalamus produces. They work by locking onto the same pituitary docking sites your body's own GHRH uses, triggering the same response.

Sermorelin: The Classic GHRH Analog

Sermorelin is a 29-amino-acid fragment of natural GHRH. It was developed in the 1970s and received FDA approval in the 1990s under the brand name Geref for pediatric growth failure. Geref was eventually pulled from the market — not for safety reasons but for commercial ones (the growth failure market was small and dominated by recombinant HGH).

After Geref's withdrawal, sermorelin continued to be available through 503A compounding pharmacies. Decades of clinical use have established it as the entry-level GH-axis peptide for anti-aging and longevity protocols. It's well-tolerated, inexpensive to compound, and produces meaningful but modest effects.

In published protocols: Sermorelin is administered as a subcutaneous injection before bed. Daily dosing is standard because sermorelin's half-life is short (about 12 minutes). The nightly timing aligns with the body's natural GH pulse during early sleep, amplifying the natural rhythm rather than replacing it. Specific dosing is determined by the prescribing provider during intake.

What patients notice: Better sleep quality is usually the first and most consistent report — often within the first 2-3 weeks. Improved recovery from exercise, slightly better body composition, and an overall sense of feeling 'younger' emerge over 8-12 weeks of consistent use.

Limitations: Sermorelin is a relatively mild intervention. Patients expecting dramatic effects often don't get them. It's also a daily injection commitment, which some patients find inconvenient over long periods. For patients with significant GH deficiency or more aggressive body composition goals, sermorelin alone may not be enough.

Tesamorelin: The FDA-Approved Heavy Hitter

Tesamorelin is a modified GHRH analog — a 44-amino-acid peptide with a tweak that stops your body from breaking it down as fast, giving it a longer half-life and more potent GH-releasing effect than sermorelin.

Tesamorelin is currently FDA-approved under the brand name Egrifta for a specific indication: reducing the deep belly fat around your organs in HIV-associated lipodystrophy. That's a narrow approval, but it establishes tesamorelin as an FDA-approved drug with published clinical trial data on efficacy and safety.

The off-label use by longevity physicians is broader. Tesamorelin's more potent GH-releasing effect and demonstrated visceral fat reduction in trials has made it a preferred protocol for patients who want a stronger intervention than sermorelin can provide, particularly for body composition goals.

In published protocols: Tesamorelin is administered as a daily subcutaneous injection. Same nightly timing as sermorelin. Specific dosing is determined by the prescribing provider during intake.

What patients notice: The effects tend to be more pronounced than sermorelin and emerge faster. Many patients notice body composition changes (visceral fat reduction, lean mass maintenance) within 6-8 weeks. Sleep and recovery effects are similar to sermorelin in quality but often more noticeable in magnitude.

Cost: Tesamorelin is substantially more expensive than sermorelin. The monthly cost to patients is typically 2-3x higher, reflecting both the higher material cost and the branded origin of the molecule. This is the primary reason sermorelin remains the more common first-line choice.

Head-to-Head: Which Should You Choose?

The practical decision typically hinges on a few factors:

Budget. Sermorelin is the affordable option; tesamorelin is the premium option. For patients on a tight budget, sermorelin is often the right starting point, with tesamorelin available as an upgrade path if the effects of sermorelin aren't enough.

Goals. Patients whose primary goal is sleep quality and general GH optimization usually do fine on sermorelin. Patients whose primary goal is body composition (visceral fat reduction, lean mass maintenance) often respond better to tesamorelin, especially if they haven't responded well to sermorelin alone.

Prior GH peptide experience. Patients who have been on sermorelin for 6-12 months and are either not responding well or want a stronger effect are natural candidates to upgrade to tesamorelin. Patients brand-new to GH-axis peptides usually start with sermorelin unless they specifically want the stronger intervention.

Age and baseline GH status. Older patients (55+) with more significant age-related GH decline may benefit more from tesamorelin's greater potency. Younger patients (40-55) often do well on sermorelin at lower cost.

Lab response. The objective measure that matters most is IGF-1 level. Both sermorelin and tesamorelin should raise IGF-1 into the upper half of the age-adjusted normal range. If sermorelin doesn't produce the desired IGF-1 response, tesamorelin often will.

What Neither Peptide Is

Neither sermorelin nor tesamorelin is synthetic HGH. This matters both legally and biologically.

Injectable recombinant HGH (brand names like Humatrope, Genotropin, Norditropin) delivers finished hormone directly into your bloodstream, bypassing the pituitary entirely. It produces the largest GH effects, but it also carries the most significant risks (insulin resistance, edema, carpal tunnel, and at sustained high doses, potential concerns about cancer promotion). It's also illegal to prescribe for anti-aging or performance-enhancement purposes in the US — legitimate indications are limited to documented pediatric growth hormone deficiency and adult growth hormone deficiency in patients with documented pituitary failure.

Sermorelin and tesamorelin are not HGH. They stimulate your body's own GH production, preserving the natural pulsatile release pattern and the body's built-in shut-off signals that keep things from going too far. You can't overdose on these peptides the way you can on HGH because your own pituitary won't release more than it's capable of, regardless of how much signaling peptide is present.

This is also why the effects are more modest than HGH. You're amplifying the system's natural response rather than bypassing it. For most patients, this is the right tradeoff. You're extending your body's natural GH curve rather than replacing it.

Why These Are the Two Peptides Available Today

A common question from patients is why sermorelin and tesamorelin are available through legitimate 503A compounding today when several other peptides in the broader biohacker conversation aren't.

The answer is regulatory. In 2023, the FDA moved a set of peptides to Category 2 on the bulk drug substances list, effectively blocking 503A compounding pharmacies from producing them. In February 2026, the administration announced intent to restore a group of peptides back to Category 1, which would return them to legitimate compounding. As of mid-2026, the formal FDA publication of that reclassification is still pending.

Sermorelin and tesamorelin were not affected by the 2023 Category 2 action. Sermorelin has a long FDA history via Geref; tesamorelin is currently FDA-approved via Egrifta. Both have established compounding pathways that the 2023 reclassification didn't touch. This is why they remain the two GH-axis peptides that can be legitimately prescribed through 503A compounding today.

For patients who want GH-axis peptide therapy today, sermorelin and tesamorelin are the two options.

Stacking With Other Longevity Interventions

Neither sermorelin nor tesamorelin is usually taken in isolation by patients who are serious about longevity optimization. The most common pairings:

NAD+ injectable. The GH-axis supports anabolic processes and recovery; NAD+ supports cellular energy and DNA repair. Together they address a broader slice of the aging process.

Rapamycin. The GH axis supports cell growth and muscle maintenance; rapamycin inhibits mTOR and promotes cellular autophagy. These might sound opposed, but used together with appropriate timing (rapamycin pulsed weekly, GH peptides daily), they produce complementary rather than conflicting effects.

Testosterone (men or women). Testosterone and GH synergize for muscle maintenance, body composition, and sexual function. The combination is common in longevity protocols for both sexes.

Exercise, especially resistance training. GH peptides alone do not build muscle. Combined with resistance training and adequate protein intake, they optimize the body's response to the work you're already doing.

Patients who add sermorelin or tesamorelin to an already-optimized base (exercise, sleep, nutrition, stress management) generally see the clearest benefits. Patients who expect the peptide to substitute for the basics tend to be disappointed.